Protective effects of Panax Ginseng against 131I-induced genotoxicity in patients with differentiated thyroid cancer.
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
received:
28
03
2022
accepted:
06
10
2022
medline:
30
3
2024
pubmed:
30
3
2024
entrez:
30
3
2024
Statut:
ppublish
Résumé
Radioiodine (131I) therapy (RAIT) is associated with oxidative stress (OS)-induced DNA damage in patients with differentiated thyroid cancer (DTC). The goal of this study was to evaluate the possible ameliorating effects of Panax Ginseng (PG) on RAIT-induced genotoxicity in patients with DTC. Forty DTC patients who had received 131I (100 to 175 mCi) were enrolled in this study. The patients were randomly classified (n = 10) into control, placebo, PG1 groups (receiving 500 mg/day of PG for 2 days before RAIT), and PG2 group (receiving 500 mg/day of PG for 2 days before to 1 day after RAIT). Blood samples were collected before and 2 days after RAIT. Lymphocyte micronuclei (MN) frequency was measured using the MN assay. Serum total antioxidant capacity (TAC) and ischemia-modified albumin (IMA) were measured using colorimetric assays. Serum albumin, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using commercial kits. The mean of baseline MN frequency was the same in the four groups. RAIT increased the MN frequencies to at least three times the baseline values in the control (39 ± 5) and placebo groups (38 ± 6) (P < 0.001). PG caused a significant decrease in the MN frequencies in the treated groups compared to the control and placebo groups (P < 0.001). RAIT and PG administration had no significant effects on the serum IMA, TAC, and markers of liver and kidney toxicity. PG could be considered a useful remedy for the protection against RAIT-induced chromosomal damage in DCT patients.
Sections du résumé
BACKGROUND
BACKGROUND
Radioiodine (131I) therapy (RAIT) is associated with oxidative stress (OS)-induced DNA damage in patients with differentiated thyroid cancer (DTC). The goal of this study was to evaluate the possible ameliorating effects of Panax Ginseng (PG) on RAIT-induced genotoxicity in patients with DTC.
MATERIALS AND METHODS
METHODS
Forty DTC patients who had received 131I (100 to 175 mCi) were enrolled in this study. The patients were randomly classified (n = 10) into control, placebo, PG1 groups (receiving 500 mg/day of PG for 2 days before RAIT), and PG2 group (receiving 500 mg/day of PG for 2 days before to 1 day after RAIT). Blood samples were collected before and 2 days after RAIT. Lymphocyte micronuclei (MN) frequency was measured using the MN assay. Serum total antioxidant capacity (TAC) and ischemia-modified albumin (IMA) were measured using colorimetric assays. Serum albumin, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using commercial kits.
RESULTS
RESULTS
The mean of baseline MN frequency was the same in the four groups. RAIT increased the MN frequencies to at least three times the baseline values in the control (39 ± 5) and placebo groups (38 ± 6) (P < 0.001). PG caused a significant decrease in the MN frequencies in the treated groups compared to the control and placebo groups (P < 0.001). RAIT and PG administration had no significant effects on the serum IMA, TAC, and markers of liver and kidney toxicity.
CONCLUSION
CONCLUSIONS
PG could be considered a useful remedy for the protection against RAIT-induced chromosomal damage in DCT patients.
Identifiants
pubmed: 38554338
doi: 10.4103/jcrt.jcrt_683_22
pii: 01363817-202420010-00048
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
304-310Informations de copyright
Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.
Références
Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer–what should (and what should not) be done. Nat Rev Endocrinol 2018;14:538–51.
Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy:A review of the literature of the past decade. Eur J Nucl Med Mol Imaging 2020;47:78–83.
Hamivand Z, Haddadi G, Fardid R. Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated thyroid cancer. J Med Phys 2018;43:41–5.
Singer MC, Marchal F, Angelos P, Bernet V, Boucai L, Buchholzer S, et al. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer:American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head Neck 2020;42:3446–59.
Reza S, Sultana S, Begum F, Perveen R, Jabin Z, Nahar N, et al. Delayed citrus stimulation and prevention of salivary glands damage in patients of thyroid carcinoma treated by radioiodine therapy. Bangladesh J Nuclear Med 2019;21:92–6.
Duskin-Bitan H, Leibner A, Amitai O, Diker-Cohen T, Hirsch D, Benbassat C, et al. Bone-marrow suppression in elderly patients following empiric radioiodine therapy:Real-life data. Thyroid 2019;29:683–91.
Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia 2018;32:952–9.
Verburg FA, Hoffmann M, Iakovou I, Konijnenberg MW, Mihailovic J, Gabina PM, et al. Errare humanum est, sed in errare perseverare diabolicum:Methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies. Springer 2020;47:519–22.
Sengoz T, Kilic-Toprak E, Yaylali O, Kilic-Erkek O, Ozdemir Y, Oymak B, et al. Hemorheology and oxidative stress in patients with differentiated thyroid cancer following I-131 ablation/metastasis treatment. Clin Hemorheol Microcirc 2020;74:209–21.
Rakha A, Rehman K, Imran MB, Shahid M, Jahan N. Mitigation of 131I induced oxidative stress by supplementation of turmeric and green cardamom in thyroid patients. Int J Radiat Res 2022;20:29–36.
Noaparast Z, Hosseinimehr SJ. Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol 2013;9:1145–59.
Bulotta S, Capriglione F, Celano M, Pecce V, Russo D, Maggisano V. Phytochemicals in thyroid cancer:Analysis of the preclinical studies. Endocrine 2021;73:8–15.
Patel A, Kosmacek EA, Fisher KW, Goldner W, Oberley-Deegan RE. MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer. Radiat Environ Biophys 2020;59:99–109.
Arring NM, Millstine D, Marks LA, Nail LM. Ginseng as a treatment for fatigue:A systematic review. J Altern Complement Med 2018;24:624–33.
Jovanovski E, Lea-Duvnjak-Smircic, Komishon A, Au-Yeung F, Zurbau A, Jenkins AL, et al. Vascular effects of combined enriched Korean Red ginseng (Panax Ginseng) and American ginseng (Panax Quinquefolius) administration in individuals with hypertension and type 2 diabetes:A randomized controlled trial. Complement Ther Med 2020;49:102338.
Riaz M, Rahman NU, Zia-Ul-Haq M, Jaffar HZ, Manea R. Ginseng:A dietary supplement as immune-modulator in various diseases. Trends Food Sci Technol 2019;83:12–30.
Zhu H, Liu H, Zhu JH, Wang SY, Zhou SS, Kong M, et al. Efficacy of ginseng and its ingredients as adjuvants to chemotherapy in non-small cell lung cancer. Food Funct 2021;12:2225–41.
Kim HY, Kang KS, Yamabe N, Yokozawa T. Comparison of the effects of Korean ginseng and heat-processed Korean ginseng on diabetic oxidative stress. Am J Chin Med 2008;36:989–1004.
Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;550:173–9.
Kim HG, Yoo SR, Park HJ, Lee NH, Shin JW, Sathyanath R, et al. Antioxidant effects of Panax ginseng CA Meyer in healthy subjects:A randomized, placebo-controlled clinical trial. Food Chem Toxicol 2011;49:2229–35.
Shukla R, Kumar M. Role of Panax ginseng as an antioxidant after cadmium-induced hepatic injuries. Food Chem Toxicol 2009;47:769–73.
Wang W, Wang S, Liu J, Cai E, Zhu H, He Z, et al. Sesquiterpenoids from the root of Panax Ginseng protect CCl4–induced acute liver injury by anti-inflammatory and anti-oxidative capabilities in mice. Biomed Pharmacother 2018;102:412–9.
Abdel-Wahhab MA, Ahmed HH. Protective effect of Korean Panax ginseng against chromium VI toxicity and free radicals generation in rats. J Ginseng Res 2004;28:11–7.
Hu JN, Liu Z, Wang Z, Li XD, Zhang LX, Li W, et al. Ameliorative effects and possible molecular mechanism of action of black ginseng (Panax ginseng) on acetaminophen-mediated liver injury. Molecules 2017;22:664–80.
Zhang QH, Wu CF, Duan L, Yang JY. Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem Toxicol 2008;46:293–302.
Kopalli SR, Won YJ, Hwang SY, Cha KM, Kim SY, Han CK, et al. Korean Red Ginseng protects against doxorubicin-induced testicular damage:An experimental study in rats. J Funct Foods 2016;20:96–107.
Ivanova T, Han Y, Son HJ, Yun YS, Song JY. Antimutagenic effect of polysaccharide ginsan extracted from Panax ginseng. Food Chem Toxicol 2006;44:517–21.
Keshavarzi F, Rastegar M, Vessal M, Rafiei Dehbidi G, Khorsand M, Ganjkarimi AH, et al. Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria. Metab Brain Dis 2018;33:675–80.
Setoodeh S, Khorsand M, Takhshid MA. The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β-thalassemia major. J Diabetes Metab Disord 2020;19:767–74.
Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007;2:1084–104.
Guven S, Alver A, Mentese A, Ilhan FC, Calapoglu M, Unsal MA. The novel ischemia marker 'ischemia-modified albumin'is increased in normal pregnancies. Acta Obstet Gynecol Scand 2009;88:479–82.
Apak R, Güçlü K, Özyürek M, Karademir SE, Altun M. Total antioxidant capacity assay of human serum using copper (II)-neocuproine as chromogenic oxidant:The CUPRAC method. Free Radic Res 2005;39:949–61.
Hyer SL, Newbold K, Harmer CL. Early and late toxicity of radioiodine therapy:Detection and management. Endocr Pract 2010;16:1064–70.
Park SK, Hyun SH, In G, Park CK, Kwak YS, Jang YJ, et al. The antioxidant activities of Korean Red Ginseng (Panax ginseng) and ginsenosides:A systemic review through in vivo and clinical trials. J Ginseng Res 2021;45:41–7.
Farhadi M, Bakhshandeh M, Shafiei B, Mahmoudzadeh A, Hosseinimehr SJ. The radioprotective effects of nano-curcumin against genotoxicity induced by iodine-131 in patients with Differentiated Thyroid Carcinoma (DTC) by micronucleus assay. Int J Cancer Manag 2018;11:e14193.
Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, et al. Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res 2002;514:77–85.
Lee TK, O'Brien KF, Wang W, Johnke RM, Sheng C, Benhabib SM, et al. Radioprotective effect of American ginseng on human lymphocytes at 90 minutes postirradiation:A study of 40 cases. J Altern Complement Med 2010;16:561–7.
Han Y, Son SJ, Akhalaia M, Platonov A, Son HJ, Lee KH, et al. Modulation of radiation-induced disturbances of antioxidant defense systems by ginsan. Evid Based Complement Alternat Med 2005;2:529–36.
Song JY, Han SK, Bae KG, Lim DS, Son SJ, Jung IS, et al. Radioprotective effects of ginsan, an immunomodulator. Radiat Res 2003;159:768–74.
Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010;43:450–4.
Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB, et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin lab 2014;60:1703–8.
Ellidag HY, Bulbuller N, Eren E, Abusoglu S, Akgol E, Cetiner M, et al. Ischemia-modified albumin:Could it be a new oxidative stress biomarker for colorectal carcinoma?. Gut Liver 2013;7:675–80.
Ma SG, Yang LX, Bai F, Xu W, Hong B. Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism. Eur J Intern Med 2012;23:e136–40.
Vrndic OB, Radivojevic SD, Jovanovic MD, Djukic SM, Teodorovic LC, Simonovic ST. Oxidative stress in patients with differentiated thyroid cancer:Early effects of radioiodine therapy. Indian J Biochem Biophys 2014;51:223–9.